Literature DB >> 17376861

Development of in vitro correlate assays of immunity to infection with Yersinia pestis.

J Bashaw1, S Norris, S Weeks, S Trevino, J J Adamovicz, S Welkos.   

Abstract

Pneumonic plague is a severe, rapidly progressing disease for which there is no effective vaccine. Since the efficacy of new vaccines cannot be tested in humans, it is essential to develop in vitro surrogate assays that are valid predictors of immunity. The F1 capsule antigen stimulates a protective immune response to most strains of Yersinia pestis. However, strains of Y. pestis that are F1- but still virulent have been isolated, and an in vitro assay, the results which can predict protection against both F1+ and F1- strains, is needed. The virulence antigen (V) is an essential virulence factor of Y. pestis and stimulates protective antibodies. We investigated potential correlates of plague immunity that are based on anti-V antibody-mediated neutralization of Yersinia-induced macrophage cytotoxicity. The neutralizing activity of sera from mice vaccinated with an F1-V fusion candidate vaccine was determined. The decrease in the level of the apoptosis-specific enzyme caspase-3 significantly predicted survival in one- and two-dose vaccination experiments. Sera from F1-V-vaccinated nonhuman primates were evaluated with macrophage assays based on caspase-3 and on other markers manifested at the different stages in cell death. Using murine- and human-derived macrophages in microscopic and fluorescence-activated-cell-sorting-based live/dead staining assays of terminal necrosis, we demonstrated a strong association between in vitro neutralization of macrophage cytotoxicity induced by serum-treated Yersinia and in vivo protection against lethal infection. These results provide a strong base for the development of reliable in vitro correlate bioassays that are predictive of protective immunity to plague.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17376861      PMCID: PMC1865625          DOI: 10.1128/CVI.00398-06

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN: 1556-679X


  53 in total

1.  Salmonella induces macrophage death by caspase-1-dependent necrosis.

Authors:  M A Brennan; B T Cookson
Journal:  Mol Microbiol       Date:  2000-10       Impact factor: 3.501

Review 2.  Interleukin-10 and inhibition of innate immunity to Yersiniae: roles of Yops and LcrV (V antigen).

Authors:  Robert R Brubaker
Journal:  Infect Immun       Date:  2003-07       Impact factor: 3.441

3.  Construction of defined F1 negative mutants of virulent Yersinia pestis.

Authors:  P L Worsham; M P Stein; S L Welkos
Journal:  Contrib Microbiol Immunol       Date:  1995

Review 4.  Caspases: enemies within.

Authors:  N A Thornberry; Y Lazebnik
Journal:  Science       Date:  1998-08-28       Impact factor: 47.728

5.  Fraction 1 capsular antigen (F1) purification from Yersinia pestis CO92 and from an Escherichia coli recombinant strain and efficacy against lethal plague challenge.

Authors:  G P Andrews; D G Heath; G W Anderson; S L Welkos; A M Friedlander
Journal:  Infect Immun       Date:  1996-06       Impact factor: 3.441

6.  Pathology of experimental pneumonic plague produced by fraction 1-positive and fraction 1-negative Yersinia pestis in African green monkeys (Cercopithecus aethiops).

Authors:  K J Davis; D L Fritz; M L Pitt; S L Welkos; P L Worsham; A M Friedlander
Journal:  Arch Pathol Lab Med       Date:  1996-02       Impact factor: 5.534

7.  Passive immunity to infection with Yersinia spp. mediated by anti-recombinant V antigen is dependent on polymorphism of V antigen.

Authors:  A Roggenkamp; A M Geiger; L Leitritz; A Kessler; J Heesemann
Journal:  Infect Immun       Date:  1997-02       Impact factor: 3.441

8.  Passive immunity to yersiniae mediated by anti-recombinant V antigen and protein A-V antigen fusion peptide.

Authors:  V L Motin; R Nakajima; G B Smirnov; R R Brubaker
Journal:  Infect Immun       Date:  1994-10       Impact factor: 3.441

9.  Association between virulence of Yersinia pestis and suppression of gamma interferon and tumor necrosis factor alpha.

Authors:  R Nakajima; R R Brubaker
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

10.  Active immunization with recombinant V antigen from Yersinia pestis protects mice against plague.

Authors:  S E Leary; E D Williamson; K F Griffin; P Russell; S M Eley; R W Titball
Journal:  Infect Immun       Date:  1995-08       Impact factor: 3.441

View more
  38 in total

1.  Single-dose combination nanovaccine induces both rapid and long-lived protection against pneumonic plague.

Authors:  Danielle A Wagner; Sean M Kelly; Andrew C Petersen; Nathan Peroutka-Bigus; Ross J Darling; Bryan H Bellaire; Michael J Wannemuehler; Balaji Narasimhan
Journal:  Acta Biomater       Date:  2019-10-11       Impact factor: 8.947

2.  Modified caspase-3 assay indicates correlation of caspase-3 activity with immunity of nonhuman primates to Yersinia pestis infection.

Authors:  Susan Welkos; Sarah Norris; Jeffrey Adamovicz
Journal:  Clin Vaccine Immunol       Date:  2008-05-14

3.  Flagellin adjuvanted F1/V subunit plague vaccine induces T cell and functional antibody responses with unique gene signatures.

Authors:  Fahreta Hamzabegovic; Johannes B Goll; William F Hooper; Sharon Frey; Casey E Gelber; Getahun Abate
Journal:  NPJ Vaccines       Date:  2020-01-23       Impact factor: 7.344

4.  Amino acid residues 196-225 of LcrV represent a plague protective epitope.

Authors:  Lauriane E Quenee; Bryan J Berube; Joshua Segal; Derek Elli; Nancy A Ciletti; Deborah Anderson; Olaf Schneewind
Journal:  Vaccine       Date:  2009-12-10       Impact factor: 3.641

5.  YopR impacts type III needle polymerization in Yersinia species.

Authors:  Bill Blaylock; Bryan J Berube; Olaf Schneewind
Journal:  Mol Microbiol       Date:  2009-12-07       Impact factor: 3.501

6.  D27-pLpxL, an avirulent strain of Yersinia pestis, primes T cells that protect against pneumonic plague.

Authors:  Frank M Szaba; Lawrence W Kummer; Lindsey B Wilhelm; Jr-Shiuan Lin; Michelle A Parent; Sara W Montminy-Paquette; Egil Lien; Lawrence L Johnson; Stephen T Smiley
Journal:  Infect Immun       Date:  2009-07-20       Impact factor: 3.441

7.  Yersinia pestis can bypass protective antibodies to LcrV and activation with gamma interferon to survive and induce apoptosis in murine macrophages.

Authors:  Betty L Noel; Sarit Lilo; Daniel Capurso; Jim Hill; James B Bliska
Journal:  Clin Vaccine Immunol       Date:  2009-08-26

8.  Multiple antigens of Yersinia pestis delivered by live recombinant attenuated Salmonella vaccine strains elicit protective immunity against plague.

Authors:  Shilpa Sanapala; Hannah Rahav; Hetal Patel; Wei Sun; Roy Curtiss
Journal:  Vaccine       Date:  2016-04-06       Impact factor: 3.641

9.  In vitro intracellular trafficking of virulence antigen during infection by Yersinia pestis.

Authors:  Tracy L DiMezzo; Gordon Ruthel; Ernst E Brueggemann; Harry B Hines; Wilson J Ribot; Carol E Chapman; Bradford S Powell; Susan L Welkos
Journal:  PLoS One       Date:  2009-07-17       Impact factor: 3.240

10.  The role of relA and spoT in Yersinia pestis KIM5 pathogenicity.

Authors:  Wei Sun; Kenneth L Roland; Christine G Branger; Xiaoying Kuang; Roy Curtiss
Journal:  PLoS One       Date:  2009-08-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.